Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 13/20 | 0.39 |
| ▸ | CNR1 | P21554 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.34 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23330855 | 0.81 | CNR2 (0.36) | CNR2CNR1SMN1; SMN2F2RL1TNNI3K | |
| SCHEMBL17269955 | 0.74 | POLB (0.40) | CNR2SMN1; SMN2MAPT | |
| SCHEMBL30135454 | 0.74 | CNR2 (0.51) | CNR2CNR1SMN1; SMN2PDE10A | |
| SCHEMBL24393197 | 0.73 | ALDH1A1 (0.41) | CNR2SMN1; SMN2 | |
| SCHEMBL23330854 | 0.72 | CNR2 (0.38) | CNR2CNR1F2RL1MAP3K12PDE10A | |
| SCHEMBL26711595 | 0.72 | TRPV1 (0.42) | CNR2HRH3MAP3K12PDE10A | |
| SCHEMBL29224929 | 0.72 | HRH3 (0.34) | CNR2CNR1SMN1; SMN2HRH3MAPT | |
| SCHEMBL30463633 | 0.72 | HRH3 (0.34) | CNR2CNR1SMN1; SMN2HRH3MAPT | |
| SCHEMBL27144457 | 0.72 | PDCD1 (0.41) | CNR2CNR1PDE10A | |
| SCHEMBL3767624 | 0.70 | MAPK1 (0.42) | CNR2SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | JING MEDICINE TECHNOLOGY (SHANGHAI) LTD. (CN) | 2023-01-26 | — | — | US | disclosed |
| WO-2021083380-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海科技大学 | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028221-A1 | EED INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | CYP4F11, CYP4A11, HSD11B1 | CNR2 3520/4885CNR1 2983/4885SMN1; SMN2 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.